Recent developments of DNA poisons--human DNA topoisomerase IIα inhibitors--as anticancer agents

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• DNA topoisomerases regulate DNA topology, essential for vital cellular processes like replication and transcription.
• These enzymes are key targets for anticancer drugs, with several DNA poisons currently in clinical use.
• Existing topoisomerase IIα inhibitors can cause severe side effects, notably cardiotoxicity.

Purpose of the Study:

• To review recent advancements in the development of DNA poisons targeting human topoisomerase IIα.
• To highlight structure-based molecular design strategies for novel anticancer agents.
• To provide a medicinal chemist's perspective on current drug design efforts.

Main Methods:

• Review of recent literature on DNA topoisomerase IIα inhibitors.
• Analysis of structure-activity relationships for various chemical classes of DNA poisons.
• Discussion of clinical progress and challenges in anticancer drug development.

Main Results:

• Several novel DNA poison compounds have been developed, showing promise in overcoming cardiotoxicity.
• New compounds targeting human topoisomerase IIα have entered clinical studies.
• Structure-based design has facilitated the development of improved anticancer agents.

Conclusions:

• Continued research into DNA topoisomerase IIα inhibitors is vital for developing safer and more effective anticancer therapies.
• Structure-based molecular design offers a promising avenue for creating novel anticancer drugs with reduced side effects.
• The field is advancing towards clinically viable treatments with enhanced safety profiles.